Received Feb 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | UNK | — | — |
felt like going to pass out; Patient did have a fever, like 101; Shivering; This is a spontaneous report received from a Physician. A patient (age and gender not provided) received meningococcal group b Rlp2086 (TRUMENBA), on 27Jan2026 as dose number unknown, single (Batch/Lot number: unknown) for immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 27Jan2026 as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LOSS OF CONSCIOUSNESS (medically significant), outcome "unknown", described as "felt like going to pass out"; CHILLS (non-serious), outcome "recovering", described as "Shivering"; PYREXIA (non-serious), outcome "unknown", described as "Patient did have a fever, like 101". The patient underwent the following laboratory tests and procedures: Body temperature: 101 Fahrenheit. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product to the development of the reported event LOSS OF CONSCIOUSNESS cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate
Test Name: Body temperature; Result Unstructured Data: Test Result:101 Fahrenheit